Earnings before income tax, amortisation and depreciation (EBITDA) stood at EUR 321.7m, up almost 14% over the year before. Exports accounted for nearly 93% of sales.

Sales in Eastern Europe, which accounts for 35.6% of total sales, surged 21%. In Russia, the biggest single market, sales rose 22% to EUR 298m. Central European sales remained roughly level at EUR 282.9m. In Western European and overseas markets sales declined 4% to EUR 257.7m and in Slovenia they fell 6% to EUR 86.6m.

Prescription drugs remain the company's main sales group, with revenue totalling EUR 980.9%, an increase of 4% over the year before. In 2014 Krka plans a marginal increase in sales and profit that is projected to be level with that for 2013.

Investments are to top EUR 164m, up from EUR 157m in 2013, according to Colarič.